TY - JOUR
T1 - Natural history of pancreatic cystic lesions
T2 - A multicenter prospective observational study for evaluating the risk of pancreatic cancer
AU - NSPINAL study group
AU - Ohno, Eizaburo
AU - Hirooka, Yoshiki
AU - Kawashima, Hiroki
AU - Ishikawa, Takuya
AU - Kanamori, Akira
AU - Ishikawa, Hideki
AU - Sasaki, Yoji
AU - Nonogaki, Koji
AU - Hara, Kazuo
AU - Hashimoto, Senju
AU - Matsubara, Hiroshi
AU - Hirai, Takanori
AU - Sumi, Hajime
AU - Sugimoto, Hiroyuki
AU - Goto, Hidemi
N1 - Publisher Copyright:
© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd
PY - 2018/1
Y1 - 2018/1
N2 - Background and Aim: The aim of this study is to elucidate the natural history of pancreatic cystic lesions (PCLs), including branch duct-type intraductal papillary mucinous neoplasm (BD-IPMN), via midterm follow-up analysis of a multicenter prospective observational study (NSPINAL study). Methods: From July 2011 to October 2016, 881 patients with PCLs were enrolled in NSPINAL study, and 664 patients with > 12 months of follow up were analyzed. Every patient was asymptomatic, and endoscopic ultrasound was performed at the initial diagnosis to exclude high-risk individuals. Follow up included endoscopic ultrasound, computed tomography, or magnetic resonance imaging at least once a year. Serial morphological changes and the pancreatic cancer (PC) incidence, including malignant progression of PCLs, were evaluated. Results: The 664 patients (358 men) were followed for a median of 33.5 months (interquartile range 29). The cyst and main pancreatic duct sizes were 16.6 ± 9.3 and 2.3 ± 1.0 mm, respectively. Morphologically, 518 cases were multilocular, 137 were unilocular, and 9 had a honeycomb pattern; 269 cases involved multifocal lesions. Ninety-six patients (14.5%) showed worsening progression on imaging. There were two resectable and four unresectable cases of pancreatic ductal adenocarcinoma and three cases of malignant BD-IPMN. The 3-year risk of developing PC was 1.2%. The standardized incidence ratio for PC among PCLs was 10.0 (95% confidence interval 3.5–16.5), and the standardized incidence ratio among BD-IPMN was 16.6 (95% confidence interval 5.1–28.1). Multivariate analysis showed that development of symptoms and worsening progression were significant predictors of PC. Conclusions: Malignant progression of PCLs, including PC development, is not uncommon. Patients with PCLs should be carefully monitored to detect pancreatic ductal adenocarcinoma at early stages.
AB - Background and Aim: The aim of this study is to elucidate the natural history of pancreatic cystic lesions (PCLs), including branch duct-type intraductal papillary mucinous neoplasm (BD-IPMN), via midterm follow-up analysis of a multicenter prospective observational study (NSPINAL study). Methods: From July 2011 to October 2016, 881 patients with PCLs were enrolled in NSPINAL study, and 664 patients with > 12 months of follow up were analyzed. Every patient was asymptomatic, and endoscopic ultrasound was performed at the initial diagnosis to exclude high-risk individuals. Follow up included endoscopic ultrasound, computed tomography, or magnetic resonance imaging at least once a year. Serial morphological changes and the pancreatic cancer (PC) incidence, including malignant progression of PCLs, were evaluated. Results: The 664 patients (358 men) were followed for a median of 33.5 months (interquartile range 29). The cyst and main pancreatic duct sizes were 16.6 ± 9.3 and 2.3 ± 1.0 mm, respectively. Morphologically, 518 cases were multilocular, 137 were unilocular, and 9 had a honeycomb pattern; 269 cases involved multifocal lesions. Ninety-six patients (14.5%) showed worsening progression on imaging. There were two resectable and four unresectable cases of pancreatic ductal adenocarcinoma and three cases of malignant BD-IPMN. The 3-year risk of developing PC was 1.2%. The standardized incidence ratio for PC among PCLs was 10.0 (95% confidence interval 3.5–16.5), and the standardized incidence ratio among BD-IPMN was 16.6 (95% confidence interval 5.1–28.1). Multivariate analysis showed that development of symptoms and worsening progression were significant predictors of PC. Conclusions: Malignant progression of PCLs, including PC development, is not uncommon. Patients with PCLs should be carefully monitored to detect pancreatic ductal adenocarcinoma at early stages.
UR - http://www.scopus.com/inward/record.url?scp=85039440734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85039440734&partnerID=8YFLogxK
U2 - 10.1111/jgh.13967
DO - 10.1111/jgh.13967
M3 - Article
C2 - 28872701
AN - SCOPUS:85039440734
SN - 0815-9319
VL - 33
SP - 320
EP - 328
JO - Journal of Gastroenterology and Hepatology (Australia)
JF - Journal of Gastroenterology and Hepatology (Australia)
IS - 1
ER -